NVCR vs. MRK
Compare and contrast key facts about NovoCure Limited (NVCR) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVCR or MRK.
Key characteristics
| NVCR | MRK | |
|---|---|---|
| YTD Return | 40.99% | 21.60% |
| 1Y Return | -73.90% | 16.59% |
| 3Y Return (Ann) | -51.08% | 24.63% |
| 5Y Return (Ann) | -16.05% | 15.40% |
| Sharpe Ratio | -0.83 | 0.93 |
| Daily Std Dev | 87.57% | 17.60% |
| Max Drawdown | -95.07% | -68.63% |
| Current Drawdown | -90.67% | -0.17% |
Fundamentals
| NVCR | MRK | |
|---|---|---|
| Market Cap | $1.77B | $329.42B |
| EPS | -$1.81 | $0.90 |
| PEG Ratio | -0.47 | 0.10 |
| Revenue (TTM) | $525.66M | $61.40B |
| Gross Profit (TTM) | $423.58M | $42.08B |
| EBITDA (TTM) | -$195.61M | $21.21B |
Correlation
The correlation between NVCR and MRK is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVCR vs. MRK - Performance Comparison
In the year-to-date period, NVCR achieves a 40.99% return, which is significantly higher than MRK's 21.60% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVCR vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVCR vs. MRK - Dividend Comparison
NVCR has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.28%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRK Merck & Co., Inc. | 2.28% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.42% | 3.11% | 3.45% |
Drawdowns
NVCR vs. MRK - Drawdown Comparison
The maximum NVCR drawdown since its inception was -95.07%, which is greater than MRK's maximum drawdown of -68.63%. Use the drawdown chart below to compare losses from any high point for NVCR and MRK. For additional features, visit the drawdowns tool.
Volatility
NVCR vs. MRK - Volatility Comparison
NovoCure Limited (NVCR) has a higher volatility of 19.33% compared to Merck & Co., Inc. (MRK) at 4.77%. This indicates that NVCR's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVCR vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between NovoCure Limited and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities